Patient advocates and some Utah pharmacists have been raising awareness about cannabis products containing delta-8 THC due to its potential health effects.
After listening to researchers and reviewing literature on the matter, the Utah Cannabinoid Product Board voted unanimously to take a stance against analog cannabinoids.
Dr. Perry Fine, chair of the board, said “at this time, there is no evidence of therapeutic benefit of the analog derived synthesized cannabinoids, including delta-8 THC.”
“Risks have been described by federal regulatory bodies and peer reviewed publications regarding delta-8 THC,” Fine said. “At this time, we do not support any therapeutic uses of analog cannabis products.”
To read the complete article, go to www.kuer.org
